674 related articles for article (PubMed ID: 21396478)
1. Urantide alleviates monocrotaline induced pulmonary arterial hypertension in Wistar rats.
Mei Y; Jin H; Tian W; Wang H; Wang H; Zhao Y; Zhang Z; Meng F
Pulm Pharmacol Ther; 2011 Aug; 24(4):386-93. PubMed ID: 21396478
[TBL] [Abstract][Full Text] [Related]
2. Urantide improves the structure and function of right ventricle as determined by echocardiography in monocrotaline-induced pulmonary hypertension rat model.
Wang Y; Tian W; Xiu C; Yan M; Wang S; Mei Y
Clin Rheumatol; 2019 Jan; 38(1):29-35. PubMed ID: 29362961
[TBL] [Abstract][Full Text] [Related]
3. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats.
Porvasnik SL; Germain S; Embury J; Gannon KS; Jacques V; Murray J; Byrne BJ; Shacham S; Al-Mousily F
J Pharmacol Exp Ther; 2010 Aug; 334(2):364-72. PubMed ID: 20430844
[TBL] [Abstract][Full Text] [Related]
4. Urotensin inhibition with palosuran could be a promising alternative in pulmonary arterial hypertension.
Onat AM; Pehlivan Y; Turkbeyler IH; Demir T; Kaplan DS; Ceribasi AO; Orkmez M; Tutar E; Taysi S; Sayarlioglu M; Kisacik B
Inflammation; 2013 Apr; 36(2):405-12. PubMed ID: 23100033
[TBL] [Abstract][Full Text] [Related]
5. Effects of atorvastatin and L-arginine treatments on electrical field stimulation-mediated relaxations in pulmonary arterial rings of monocrotaline-induced pulmonary hypertensive rats.
Ozturk EI; Uma S
J Cardiovasc Pharmacol; 2010 Nov; 56(5):498-505. PubMed ID: 20729759
[TBL] [Abstract][Full Text] [Related]
6. Role of nitric oxide and endothelin-1 in monocrotaline-induced pulmonary hypertension in rats.
Mathew R; Zeballos GA; Tun H; Gewitz MH
Cardiovasc Res; 1995 Nov; 30(5):739-46. PubMed ID: 8595621
[TBL] [Abstract][Full Text] [Related]
7. Preventive treatment with atorvastatin ameliorates endothelial dysfunction of small pulmonary arteries in monocrotaline-induced pulmonary hypertensive rats.
Lin Z; Jiang Z; Huang X; Cai X; Wang H; Xie L
Clin Exp Hypertens; 2017; 39(6):495-501. PubMed ID: 28628347
[TBL] [Abstract][Full Text] [Related]
8. JTV-506, a new K(ATP) channel opener, relaxes pulmonary artery isolated from monocrotaline-treated pulmonary hypertensive rats.
Tsutsumi Y; Makita T; Yamaguchi K; Shibata O; Sumikawa K
J Anesth; 2004; 18(3):210-5. PubMed ID: 15290421
[TBL] [Abstract][Full Text] [Related]
9. Effects of endogenous sulfur dioxide on monocrotaline-induced pulmonary hypertension in rats.
Jin HF; Du SX; Zhao X; Wei HL; Wang YF; Liang YF; Tang CS; Du JB
Acta Pharmacol Sin; 2008 Oct; 29(10):1157-66. PubMed ID: 18817619
[TBL] [Abstract][Full Text] [Related]
10. A novel Ca2+ channel antagonist reverses cardiac hypertrophy and pulmonary arteriolar remodeling in experimental pulmonary hypertension.
Pereira SL; Kummerle AE; Fraga CA; Barreiro EJ; Rocha Nde N; Ferraz EB; do Nascimento JH; Sudo RT; Zapata-Sudo G
Eur J Pharmacol; 2013 Feb; 702(1-3):316-22. PubMed ID: 23399770
[TBL] [Abstract][Full Text] [Related]
11. [Fasudil reverses monocrotaline-induced pulmonary hypertension in rats].
Jiang H; Guan RJ; Wang HY
Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Mar; 41(3):239-44. PubMed ID: 23879951
[TBL] [Abstract][Full Text] [Related]
12. Preventive and remedial application of etanercept attenuate monocrotaline-induced pulmonary arterial hypertension.
Zhang LL; Lu J; Li MT; Wang Q; Zeng XF
Int J Rheum Dis; 2016 Feb; 19(2):192-8. PubMed ID: 24612527
[TBL] [Abstract][Full Text] [Related]
13. Endothelial nitric oxide synthase-enhancing G-protein coupled receptor antagonist inhibits pulmonary artery hypertension by endothelin-1-dependent and endothelin-1-independent pathways in a monocrotaline model.
Liu CP; Dai ZK; Huang CH; Yeh JL; Wu BN; Wu JR; Chen IJ
Kaohsiung J Med Sci; 2014 Jun; 30(6):267-78. PubMed ID: 24835346
[TBL] [Abstract][Full Text] [Related]
14. Palosuran treatment effective as bosentan in the treatment model of pulmonary arterial hypertension.
Pehlivan Y; Dokuyucu R; Demir T; Kaplan DS; Koc I; Orkmez M; Turkbeyler IH; Ceribasi AO; Tutar E; Taysi S; Kisacik B; Onat AM
Inflammation; 2014 Aug; 37(4):1280-8. PubMed ID: 24604341
[TBL] [Abstract][Full Text] [Related]
15. Ang-(1-7) might prevent the development of monocrotaline induced pulmonary arterial hypertension in rats.
Chen L; Xiao J; Li Y; Ma H
Eur Rev Med Pharmacol Sci; 2011 Jan; 15(1):1-7. PubMed ID: 21381494
[TBL] [Abstract][Full Text] [Related]
16. N-acylhydrazone derivative ameliorates monocrotaline-induced pulmonary hypertension through the modulation of adenosine AA2R activity.
Alencar AK; Pereira SL; da Silva FE; Mendes LV; Cunha Vdo M; Lima LM; Montagnoli TL; Caruso-Neves C; Ferraz EB; Tesch R; Nascimento JH; Sant'anna CM; Fraga CA; Barreiro EJ; Sudo RT; Zapata-Sudo G
Int J Cardiol; 2014 May; 173(2):154-62. PubMed ID: 24630383
[TBL] [Abstract][Full Text] [Related]
17. Attenuation of monocrotaline-induced pulmonary arterial hypertension in rats by rosuvastatin.
Li XL; Guan RJ; Li JJ
J Cardiovasc Pharmacol; 2012 Aug; 60(2):219-26. PubMed ID: 22592772
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary arterial hypertension induced by a novel method: Twice-intraperitoneal injection of monocrotaline.
Zhuang W; Lian G; Huang B; Du A; Xiao G; Gong J; Xu C; Wang H; Xie L
Exp Biol Med (Maywood); 2018 Aug; 243(12):995-1003. PubMed ID: 30099957
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib alleviates experimental pulmonary arterial hypertension.
Kim SY; Lee JH; Huh JW; Kim HJ; Park MK; Ro JY; Oh YM; Lee SD; Lee YS
Am J Respir Cell Mol Biol; 2012 Nov; 47(5):698-708. PubMed ID: 22842494
[TBL] [Abstract][Full Text] [Related]
20. Amlodipine prevents monocrotaline-induced pulmonary arterial hypertension and prolongs survival in rats independent of blood pressure lowering.
Mawatari E; Hongo M; Sakai A; Terasawa F; Takahashi M; Yazaki Y; Kinoshita O; Ikeda U
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):594-600. PubMed ID: 17581214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]